| Cash Flow | 2026-03-31 |
|---|---|
| Revenues | 23,193 |
| Personnel costs | 11,895 |
| Materials and non-depreciation overhead | 8,856 |
| Depreciation | 2,310 |
| Stock-based compensation | 1,698 |
| Reorganization costs | 1,543 |
| Loss on sale or disposal of assets | 0 |
| All other operating expenses | 1,563 |
| Interest expense, net | -7,220 |
| Change in fair value of debt derivative liability | -3,155 |
| Other income, net | 110 |
| Income tax expense (benefit) | 43 |
| Net loss | -14,980 |
| Depreciation | 2,310 |
| Stock-based compensation | 1,698 |
| Non-cash interest expense, inclusive of related party | 7,084 |
| Change in fair value of debt derivative liability, related party | -3,155 |
| Loss on sale or disposal of assets | 0 |
| Other, net | 46 |
| Accounts receivable, inclusive of related party | -6,771 |
| Contract assets | 206 |
| Inventory | -930 |
| Other assets | -209 |
| Accounts payable | 1,427 |
| Accrued expenses and other liabilities | -3,652 |
| Net cash provided by operating activities | 4,700 |
| Purchases of property, plant, and equipment | 1,118 |
| Proceeds from sale of equipment | 0 |
| Net cash (used in) provided by investing activities | -1,118 |
| Payments on revolving credit facility | 36,400 |
| Proceeds from revolving credit facility | 36,400 |
| Payments related to employee stock plans | 0 |
| Other financing activities | -256 |
| Net cash used in financing activities | -256 |
| Net increase (decrease) in cash and cash equivalents | 3,326 |
| Cash and cash equivalents, beginning of period | 17,469 |
| Cash and cash equivalents, end of period | 20,795 |
LIFECORE BIOMEDICAL, INC. DE (LFCR)
LIFECORE BIOMEDICAL, INC. DE (LFCR)